Copy to clipboard 
DJO reported 4Q21 orthopedic sales of $155.2 million, +76.5% vs. 4Q20. For the full year 2021, the company generated $466.9 in orthopedic sales, +48.8% vs. 2020. While the outsized growth is attributable to the host of acquisitions DJO made, the company’s organic sales still grew in the mid-single digits.
At the end of 1Q21, Colfax will complete the separation of its MedTech (Enovis) and fabrication (ESAB) businesses. The executive team offered scant strategic or forecast details in its 4Q earnings call, and instead reserved those discussions for its upcoming March 14 investor event introducing the two companies.
Enovis expects total sales growth of 10% to 14%, with 6% to 9% of that coming from organic growth.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 4Q21 | 4Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $127.2 | $72.5 | $54.6 | 75.3% |
| Knees | $17.3 | $10.2 | $7.1 | 70.2% |
| Hips | $42.2 | $23.9 | $18.2 | 76.2% |
| Extremities | $67.7 | $38.4 | $29.3 | 76.2% |
| Trauma | $11.1 | $0.0 | $0.0 | 0% |
| Other (CMF) | $17.0 | $15.4 | $1.6 | 10.1% |
| Total | $155.2 | $87.9 | $67.3 | 76.5% |
| FY20 | FY19 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $373.1 | $257.6 | $115.6 | 44.9% |
| Knees | $52.1 | $38.1 | $14.0 | 36.7% |
| Hips | $122.9 | $89.6 | $33.2 | 37.1% |
| Extremities | $198.2 | $129.8 | $68.4 | 52.7% |
| Trauma | $27.0 | |||
| Other (CMF) | $66.7 | $56.1 | $10.6 | 18.9% |
| Total | $466.9 | $313.7 | $153.2 | 48.8% |
Orthopedic Sales by Geography
| 4Q21 | 4Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $102.4 | $64.2 | $38.2 | 59.6% |
| OUS | $52.8 | $23.7 | $29.0 | 122.2% |
| EMEA | $43.5 | $18.5 | $25.0 | 135.3% |
| Asia Pacific | $5.6 | $3.1 | $2.5 | 81.5% |
| Rest of World | $3.7 | $2.2 | $1.5 | 69.4% |
| Total | $155.2 | $87.9 | $67.3 | 76.5% |
| FY20 | FY19 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $320.9 | $229.8 | $91.1 | 39.6% |
| OUS | $146.0 | $83.9 | $62.1 | 74% |
| EMEA | $116.9 | $65.8 | $51.1 | 77.7% |
| Asia Pacific | $16.7 | $10.2 | $6.5 | 63.4% |
| Rest of World | $12.3 | $7.9 | $4.5 | 57.1% |
| Total | $466.9 | $313.7 | $153.2 | 48.8% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $1,023.3 | |
| Cost of Sales | $604.5 | 59.1% |
| Selling and Admin | $351.7 | 34.4% |
| Other | $67.1 | 6.6% |
| Net Earnings | ($0.0) | (0%) |
| $0.0 | 0% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
DJO reported 4Q21 orthopedic sales of $155.2 million, +76.5% vs. 4Q20. For the full year 2021, the company generated $466.9 in orthopedic sales, +48.8% vs. 2020. While the outsized growth is attributable to the host of acquisitions DJO made, the company's organic sales still grew in the mid-single digits.
At the end of 1Q21, Colfax will...
DJO reported 4Q21 orthopedic sales of $155.2 million, +76.5% vs. 4Q20. For the full year 2021, the company generated $466.9 in orthopedic sales, +48.8% vs. 2020. While the outsized growth is attributable to the host of acquisitions DJO made, the company’s organic sales still grew in the mid-single digits.
At the end of 1Q21, Colfax will complete the separation of its MedTech (Enovis) and fabrication (ESAB) businesses. The executive team offered scant strategic or forecast details in its 4Q earnings call, and instead reserved those discussions for its upcoming March 14 investor event introducing the two companies.
Enovis expects total sales growth of 10% to 14%, with 6% to 9% of that coming from organic growth.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 4Q21 | 4Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $127.2 | $72.5 | $54.6 | 75.3% |
| Knees | $17.3 | $10.2 | $7.1 | 70.2% |
| Hips | $42.2 | $23.9 | $18.2 | 76.2% |
| Extremities | $67.7 | $38.4 | $29.3 | 76.2% |
| Trauma | $11.1 | $0.0 | $0.0 | 0% |
| Other (CMF) | $17.0 | $15.4 | $1.6 | 10.1% |
| Total | $155.2 | $87.9 | $67.3 | 76.5% |
| FY20 | FY19 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $373.1 | $257.6 | $115.6 | 44.9% |
| Knees | $52.1 | $38.1 | $14.0 | 36.7% |
| Hips | $122.9 | $89.6 | $33.2 | 37.1% |
| Extremities | $198.2 | $129.8 | $68.4 | 52.7% |
| Trauma | $27.0 | |||
| Other (CMF) | $66.7 | $56.1 | $10.6 | 18.9% |
| Total | $466.9 | $313.7 | $153.2 | 48.8% |
Orthopedic Sales by Geography
| 4Q21 | 4Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $102.4 | $64.2 | $38.2 | 59.6% |
| OUS | $52.8 | $23.7 | $29.0 | 122.2% |
| EMEA | $43.5 | $18.5 | $25.0 | 135.3% |
| Asia Pacific | $5.6 | $3.1 | $2.5 | 81.5% |
| Rest of World | $3.7 | $2.2 | $1.5 | 69.4% |
| Total | $155.2 | $87.9 | $67.3 | 76.5% |
| FY20 | FY19 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $320.9 | $229.8 | $91.1 | 39.6% |
| OUS | $146.0 | $83.9 | $62.1 | 74% |
| EMEA | $116.9 | $65.8 | $51.1 | 77.7% |
| Asia Pacific | $16.7 | $10.2 | $6.5 | 63.4% |
| Rest of World | $12.3 | $7.9 | $4.5 | 57.1% |
| Total | $466.9 | $313.7 | $153.2 | 48.8% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $1,023.3 | |
| Cost of Sales | $604.5 | 59.1% |
| Selling and Admin | $351.7 | 34.4% |
| Other | $67.1 | 6.6% |
| Net Earnings | ($0.0) | (0%) |
| $0.0 | 0% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
